3-chloro-6-(pyridin-3-yl)pyridazine | 78784-66-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-chloro-6-(pyridin-3-yl)pyridazine
• 英文别名: 3-chloro-6-pyridin-3-ylpyridazine
• CAS: 78784-66-4
• 化学式: C₉H₆ClN₃
• 分子量: 191.62
• InChiKey: ORJRJVSMOMIYGH-UHFFFAOYSA-N

物化性质

• 沸点：
  406.9±30.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-chloro-6-(pyridin-3-yl)pyridazine 在 水 、 溶剂黄146 作用下， 反应 4.0h， 生成 6-(吡啶-3-基)吡嗪-3(2H)-酮
  参考文献：
  名称：

  Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

  摘要：

  合成了一系列取代有吗啉-嘧啶衍生物的吡嗪-3-酮，并评估其作为c-Met酶的酪氨酸激酶抑制剂以及对Hs746T人胃癌细胞系的抗增殖活性。大多数化合物表现出良好的生物活性，其中化合物10、12a和14a展现了优异的c-Met酶抑制活性和Hs746T细胞基础活性。

  DOI：

  10.1007/s12272-015-0703-7
• 作为产物：
  描述：

  3-吡啶硼酸 、 3-氯-6-碘哒嗪 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 0.17h， 以50%的产率得到3-chloro-6-(pyridin-3-yl)pyridazine
  参考文献：
  名称：

  Discovery of Potent, Selective, Orally Bioavailable Stearoyl-CoA Desaturase 1 Inhibitors

  摘要：

  Stearoyl-CoA desaturase 1 (SCD1) catalyzes the committed step in the biosynthesis of monounsaturated fatty acids from saturated, long-chain fatty acids. Studies with SCD1 knockout mice have established that these animals are lean and protected from leptin deficiency-induced and diet-induced obesity, with greater whole body insulin sensitivity than wild-type animals. In this work, we have discovered a series of potent, selective, orally bioavailable SCD1 inhibitors based on a known pyridazine carboxamide template. The representative lead inhibitor 28c also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

  DOI：

  10.1021/jm070219p

文献信息

• 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines
  申请人：American Cyanamid Company

  公开号：US04260756A1

  公开（公告）日：1981-04-07

  This disclosure describes novel 6- and 8-heteroaryl and substituted 6- and 8-heteroaryl-1,2,4-triazolo[4,3-b]-pyridazines and their use as agents for treating anxiety.

  这份披露描述了新颖的6-和8-杂芳基及取代的6-和8-杂芳基-1,2,4-三唑并[4,3-b]-吡啶嗪，以及它们作为治疗焦虑症的药剂的用途。
• Imidazo[1,2-b]pyridazines
  申请人：American Cyanamid Company

  公开号：US04569934A1

  公开（公告）日：1986-02-11

  This invention concerns novel imidazo[1,2-b]-pyridazines and their use as agents for treating anxiety.

  这项发明涉及新型咪唑并[1,2-b]-吡啶嗪及其作为治疗焦虑症的药物的用途。
• [EN] HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS<br/>[FR] INHIBITEURS HAUTEMENT SÉLECTIFS DE C-MET UTILISÉS COMME AGENTS ANTICANCÉREUX
  申请人：CROWN BIOSCIENCE INC TAICANG

  公开号：WO2014032498A1

  公开（公告）日：2014-03-06

  Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

  本文披露了新型含氮、杂环、c-Met抑制剂化合物，其制备方法和配方。这些化合物可用作治疗剂，用于抑制、调节和控制c-Met激酶信号通路，并用于治疗受c-Met介导的主体细胞增殖紊乱或疾病。
• Pd-Catalyzed Chemoselective Cross-Coupling Reaction of Triaryl- or Triheteroarylbismuth Compounds with 3,6-Dihalopyridazines
  作者：Karène Urgin、Christophe Aubé、Muriel Pipelier、Virginie Blot、Christine Thobie-Gautier、Stéphane Sengmany、Jacques Lebreton、Eric Léonel、Didier Dubreuil、Sylvie Condon

  DOI：10.1002/ejoc.201200977

  日期：2013.1

  The cross-coupling reactions of 3,6-dihalopyridazines with triaryl- or triheteroarylbismuth compounds were performed under palladium catalysis. The reaction was highly chemoselective, affording functionalized aryl- or heteroarylpyridazinyl chlorides in moderate to good yields.

  3,6-二卤代哒嗪与三芳基-或三杂芳基铋化合物的交叉偶联反应在钯催化下进行。该反应具有高度化学选择性，以中等至良好的产率提供官能化的芳基-或杂芳基哒嗪基氯。
• TRIAZOLOPYRIDAZINES AS KINASE MODULATORS
  申请人：Lu Tianbao

  公开号：US20090098181A1

  公开（公告）日：2009-04-16

  The invention is directed to triazolopyridazine compounds of Formula I: where R 1 , R 5 , R 6 , R 7 , R 8 , and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，使用这种化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，并使用这种化合物来减少或抑制细胞或受体中c-Met的激酶活性，调节细胞或受体中c-Met的表达，并使用这种化合物预防或治疗细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。